In the study, the investigators predicted EGFR mutational status in early stage NSCLC patients treated with a targeted therapy (Gefitinib) using the change in 89 radiomics features over 3 weeks (delta features) extracted from 1.25 mm and lung kernel images (87). This evidence concerns the gene EGFR and non-small cell lung carcinoma.